Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rosalind S Chuang

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Neuron|February 12, 2013
Parallel PARKing: Parkinson's genes function in common pathwayRosalind S Chuang, Aaron D Gitler
Movement Disorders : Official Journal of the Movement Disorder Society|September 8, 2009
Rasagiline-induced spontaneous ejaculationRosalind S Chuang, Anthony E Lang
Movement Disorders Clinical Practice|January 29, 2025
Longitudinal Changes in Patient- and Clinical-Reported Outcomes in Early Spinocerebellar Ataxia Types 1, 2, 3, and 6 from the IDEA StudyAndreea M Rawlings, Rosalind S Chuang, Jeremy D Schmahmann, et al.
Journal of Clinical Medicine|November 19, 2020
Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington's Disease Patients-A Randomized Phase 2 Clinical TrialMichael J Brownstein, Neal G Simon, Jeffrey D Long, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Neuron|February 12, 2013
Parallel PARKing: Parkinson's genes function in common pathwayRosalind S Chuang, Aaron D Gitler
Movement Disorders : Official Journal of the Movement Disorder Society|September 8, 2009
Rasagiline-induced spontaneous ejaculationRosalind S Chuang, Anthony E Lang
Movement Disorders Clinical Practice|January 29, 2025
Longitudinal Changes in Patient- and Clinical-Reported Outcomes in Early Spinocerebellar Ataxia Types 1, 2, 3, and 6 from the IDEA StudyAndreea M Rawlings, Rosalind S Chuang, Jeremy D Schmahmann, et al.
Journal of Clinical Medicine|November 19, 2020
Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington's Disease Patients-A Randomized Phase 2 Clinical TrialMichael J Brownstein, Neal G Simon, Jeffrey D Long, et al.
Pageof 1